about
Comparing gene expression data from formalin-fixed, paraffin embedded tissues and qPCR with that from snap-frozen tissue and microarrays for modeling outcomes of patients with ovarian carcinoma.Discrete mixture modeling to address genetic heterogeneity in time-to-event regressionRandomized reverse marker strategy design for prospective biomarker validationConnecting prognostic ligand receptor signaling loops in advanced ovarian cancer.Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancerDifferential antigen expression profile predicts immunoreactive subset of advanced ovarian cancersInferring active and prognostic ligand-receptor pairs with interactions in survival regression models.Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve.Postoperative visual acuity in patients with fuchs dystrophy undergoing descemet membrane-stripping automated endothelial keratoplasty: correlation with the severity of histologic changes.Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.Estimating Tree-Structured Covariance Matrices via Mixed-Integer Programming.Finding Jumps in Otherwise Smooth Curves: Identifying Critical Events in Political ProcessesA sample size formula for the supremum log-rank statistic.Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinomaQuantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding BasophilsPembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib StudyIn situ thermal ablation augments antitumor efficacy of adoptive T cell therapy
P50
Q30998420-BAAB2250-558B-48CA-8F30-8035A5A4D457Q33760422-4C81AE8D-F39A-47AE-8D91-CC123147FE63Q33934952-8401E860-AF15-491C-86BB-5A56C7BAFF92Q34224414-4AC6E2A3-37C4-4111-B350-ACE4E905536FQ34364815-3A30C9DC-718D-43C7-8BCE-902FB97C60B6Q34472941-6547BB4C-2A71-41D2-8557-6B6BDF28DB6CQ35026818-8E72F4F3-49C6-4025-B9EA-73F6A9624957Q35908928-9E04A068-BD99-4E24-ACA7-82DE2408FF51Q36240562-ABEA7A66-F633-4819-8D90-F4E0148DC786Q36546645-0FBA95A6-0936-4B32-A9BF-8A3940907E98Q36865650-DFC08727-AA41-4D5A-84DE-C5165E39E315Q37587622-5521BFBF-4928-4AE7-8440-B3F0FD36B72AQ38791320-F44284D9-BF07-4B07-96BC-2FF97BF95673Q38917442-B64E2939-3819-41F5-B68A-84A0E66BAE18Q39019970-97BDB024-7914-45B1-A2C3-8BB5C96BBD39Q41830336-C61C1D50-16BA-4BBC-A662-DBAA788872A5Q47390389-06DBD0EA-011D-4818-98D3-184D8D209400Q89581513-D70867F1-7E5B-429A-8C3B-7A2F4C828DBEQ90832754-D8C6C0BE-DA59-4FC0-8894-9F93A4B3D0CEQ91150391-AC98549A-0AF2-4333-972F-719E0C53CCE2Q91649403-2B25DA9E-0CF1-4DF8-9D98-11E0D6117FA5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kevin H Eng
@ast
Kevin H Eng
@en
Kevin H Eng
@es
Kevin H Eng
@nl
Kevin H Eng
@sl
type
label
Kevin H Eng
@ast
Kevin H Eng
@en
Kevin H Eng
@es
Kevin H Eng
@nl
Kevin H Eng
@sl
altLabel
Kevin Hasegawa Eng
@en
prefLabel
Kevin H Eng
@ast
Kevin H Eng
@en
Kevin H Eng
@es
Kevin H Eng
@nl
Kevin H Eng
@sl
P106
P21
P2456
P31
P496
0000-0001-5636-0812